Best Known For
2014 (through the generic-ruxolitinib pathway for ruxolitinib tablets)
Core Claims
- Apotex’s ruxolitinib received FDA approval in 2014
- Approval is through the generic-ruxolitinib pathway for ruxolitinib tablets
- FDA approval timing depends on the particular application/product label
Differentiators
- Approval year described as tied to the Apotex generic-ruxolitinib pathway
- Exact timing depends on the specific application/product label (brand vs. generic and dosage form)
Pricing Perception:
Not Mentioned